KYTX
Kyverna Therapeutics, Inc.
Biotechnology
Market Cap$407M
5Y Perf.-65.8%
Compare Stocks
4 / 10Try these comparisons:
Stock Comparison
KYTX vs IMVT vs CABA vs RCUS
Revenue, margins, valuation, and 5-year total return — side by side.
IMVT
Immunovant, Inc.
Biotechnology
Market Cap$5.53B
5Y Perf.-23.0%
CABA
Cabaletta Bio, Inc.
Biotechnology
Market Cap$409M
5Y Perf.-82.5%
RCUS
Arcus Biosciences, Inc.
Biotechnology
Market Cap$2.50B
5Y Perf.+29.6%
KYTX vs IMVT vs CABA vs RCUS — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | KYTX | IMVT | CABA | RCUS |
|---|---|---|---|---|
| Industry | Biotechnology | Biotechnology | Biotechnology | Biotechnology |
| Market Cap | $407M | $5.53B | $409M | $2.50B |
| Revenue (TTM) | $0.00 | $0.00 | $0.00 | $236M |
| Net Income (TTM) | $-161M | $-464M | $-168M | $-369M |
| Gross Margin | — | — | — | 90.7% |
| Operating Margin | — | — | — | -168.6% |
| Total Debt | $8M | $98K | $27M | $99M |
| Cash & Equiv. | $97M | $714M | $83M | $222M |
KYTX vs IMVT vs CABA vs RCUS — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
KYTX
IMVT
CABA
RCUS
| Stock | Feb 24 | May 26 | Return |
|---|---|---|---|
| Kyverna Therapeutic… (KYTX) | 100 | 34.2 | -65.8% |
| Immunovant, Inc. (IMVT) | 100 | 77.0 | -23.0% |
| Cabaletta Bio, Inc. (CABA) | 100 | 17.5 | -82.5% |
| Arcus Biosciences, … (RCUS) | 100 | 129.6 | +29.6% |
Price return only. Dividends and distributions are not included.
Quick Verdict: KYTX vs IMVT vs CABA vs RCUS
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: KYTX and RCUS are tied at the top with 2 categories each — the right choice depends on your priorities. Arcus Biosciences, Inc. is the stronger pick specifically for growth and revenue expansion and operational efficiency and capital deployment. IMVT also leads in specific categories worth noting. As sector peers, any of these can serve as alternatives in the same allocation.
KYTX
Kyverna Therapeutics, Inc.
The Quality Compounder
KYTX carries the broadest edge in this set and is the clearest fit for quality and momentum.
- 5.0% margin vs RCUS's -156.4%
- +360.4% vs IMVT's +96.1%
Best for: quality and momentum
IMVT
Immunovant, Inc.
The Income Pick
IMVT is the clearest fit if your priority is income & stability and long-term compounding.
- beta 1.37
- 173.6% 10Y total return vs RCUS's 45.9%
- Lower volatility, beta 1.37, Low D/E 0.0%, current ratio 11.16x
- Beta 1.37, current ratio 11.16x
Best for: income & stability and long-term compounding
CABA
Cabaletta Bio, Inc.
The Growth Play
CABA is the clearest fit if your priority is growth exposure.
- EPS growth 29.9%
Best for: growth exposure
RCUS
Arcus Biosciences, Inc.
The Growth Leader
RCUS is the #2 pick in this set and the best alternative if growth and efficiency is your priority.
- -4.3% revenue growth vs KYTX's -91.8%
- -35.3% ROA vs CABA's -90.2%, ROIC -64.1% vs -429.6%
Best for: growth and efficiency
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | RCUS | -4.3% revenue growth vs KYTX's -91.8% |
| Quality / Margins | KYTX | 5.0% margin vs RCUS's -156.4% |
| Stability / Safety | IMVT | Beta 1.37 vs KYTX's 3.05, lower leverage |
| Dividends | Tie | None of these 4 stocks pay a meaningful dividend |
| Momentum (1Y) | KYTX | +360.4% vs IMVT's +96.1% |
| Efficiency (ROA) | RCUS | -35.3% ROA vs CABA's -90.2%, ROIC -64.1% vs -429.6% |
KYTX vs IMVT vs CABA vs RCUS — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Segment breakdown not available.
Segment breakdown not available.
FY 2025
KYTX vs IMVT vs CABA vs RCUS — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLIMVTLAGGINGRCUS
Who Leads Where
CABA leads in 1 of 6 categories
IMVT leads 1 • KYTX leads 0 • RCUS leads 0 • 3 tied
Explore the data ↓RCUSArcus Biosciences, In…
0leads
KYTXKyverna Therapeutics,…
0leads
CABACabaletta Bio, Inc.
1leads
IMVTImmunovant, Inc.
1leads
6 Total Categories
CATEGORYLEADERvs CABAvs KYTXMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
CABA1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
Tied
—
Total Returns1Y, 3Y, 5Y total returns with dividends
IMVT4/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
CABA leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
RCUS and CABA operate at a comparable scale, with $236M and $0 in trailing revenue.
| Metric | KYTXKyverna Therapeut… | IMVTImmunovant, Inc. | CABACabaletta Bio, In… | RCUSArcus Biosciences… |
|---|---|---|---|---|
| RevenueTrailing 12 months | $0 | $0 | $0 | $236M |
| EBITDAEarnings before interest/tax | -$170M | -$487M | -$172M | -$391M |
| Net IncomeAfter-tax profit | -$161M | -$464M | -$168M | -$369M |
| Free Cash FlowCash after capex | -$158M | -$423M | -$132M | -$489M |
| Gross MarginGross profit ÷ Revenue | — | — | — | +90.7% |
| Operating MarginEBIT ÷ Revenue | — | — | — | -168.6% |
| Net MarginNet income ÷ Revenue | — | — | — | -156.4% |
| FCF MarginFCF ÷ Revenue | — | — | — | -2.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — | — | -39.3% |
| EPS Growth (YoY)Latest quarter vs prior year | -6.3% | +19.7% | +36.9% | +10.5% |
CABA leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — KYTX and IMVT each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | KYTXKyverna Therapeut… | IMVTImmunovant, Inc. | CABACabaletta Bio, In… | RCUSArcus Biosciences… |
|---|---|---|---|---|
| Market CapShares × price | $407M | $5.5B | $409M | $2.5B |
| Enterprise ValueMkt cap + debt − cash | $319M | $4.8B | $353M | $2.4B |
| Trailing P/EPrice ÷ TTM EPS | -2.79x | -9.97x | -2.44x | -7.54x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — |
| EV / EBITDAEnterprise value multiple | — | — | — | — |
| Price / SalesMarket cap ÷ Revenue | — | — | — | 10.11x |
| Price / BookPrice ÷ Book value/share | 1.34x | 5.83x | 3.65x | 4.22x |
| Price / FCFMarket cap ÷ FCF | — | — | — | — |
Evenly matched — KYTX and IMVT each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
Evenly matched — IMVT and RCUS each lead in 4 of 9 comparable metrics.
Profitability & Efficiency
IMVT delivers a -47.1% return on equity — every $100 of shareholder capital generates $-47 in annual profit, vs $-122 for CABA. IMVT carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to CABA's 0.24x. On the Piotroski fundamental quality scale (0–9), KYTX scores 5/9 vs RCUS's 0/9, reflecting solid financial health.
| Metric | KYTXKyverna Therapeut… | IMVTImmunovant, Inc. | CABACabaletta Bio, In… | RCUSArcus Biosciences… |
|---|---|---|---|---|
| ROE (TTM)Return on equity | -106.0% | -47.1% | -121.7% | -69.0% |
| ROA (TTM)Return on assets | -86.0% | -44.1% | -90.2% | -35.3% |
| ROICReturn on invested capital | -106.0% | — | -4.3% | -64.1% |
| ROCEReturn on capital employed | -87.4% | -66.1% | -126.2% | -42.1% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 2 | 1 | 0 |
| Debt / EquityFinancial leverage | 0.03x | 0.00x | 0.24x | 0.16x |
| Net DebtTotal debt minus cash | -$88M | -$714M | -$56M | -$123M |
| Cash & Equiv.Liquid assets | $97M | $714M | $83M | $222M |
| Total DebtShort + long-term debt | $8M | $98,000 | $27M | $99M |
| Interest CoverageEBIT ÷ Interest expense | -2204.37x | — | — | -13.38x |
Evenly matched — IMVT and RCUS each lead in 4 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
IMVT leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in IMVT five years ago would be worth $16,241 today (with dividends reinvested), compared to $3,100 for KYTX. Over the past 12 months, KYTX leads with a +360.4% total return vs IMVT's +96.1%. The 3-year compound annual growth rate (CAGR) favors IMVT at 12.1% vs KYTX's -32.3% — a key indicator of consistent wealth creation.
| Metric | KYTXKyverna Therapeut… | IMVTImmunovant, Inc. | CABACabaletta Bio, In… | RCUSArcus Biosciences… |
|---|---|---|---|---|
| YTD ReturnYear-to-date | +6.0% | +5.1% | +81.0% | +6.5% |
| 1-Year ReturnPast 12 months | +360.4% | +96.1% | +244.8% | +209.6% |
| 3-Year ReturnCumulative with dividends | -69.0% | +40.9% | -65.8% | +24.9% |
| 5-Year ReturnCumulative with dividends | -69.0% | +62.4% | -58.2% | -18.6% |
| 10-Year ReturnCumulative with dividends | -69.0% | +173.6% | -60.0% | +45.9% |
| CAGR (3Y)Annualised 3-year return | -32.3% | +12.1% | -30.1% | +7.7% |
IMVT leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
Evenly matched — IMVT and CABA each lead in 1 of 2 comparable metrics.
Risk & Volatility
IMVT is the less volatile stock with a 1.37 beta — it tends to amplify market swings less than KYTX's 3.05 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CABA currently trades 94.6% from its 52-week high vs KYTX's 68.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | KYTXKyverna Therapeut… | IMVTImmunovant, Inc. | CABACabaletta Bio, In… | RCUSArcus Biosciences… |
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 3.05x | 1.37x | 2.54x | 1.95x |
| 52-Week HighHighest price in past year | $13.67 | $30.09 | $4.23 | $28.72 |
| 52-Week LowLowest price in past year | $1.95 | $13.36 | $1.11 | $7.06 |
| % of 52W HighCurrent price vs 52-week peak | +68.0% | +90.5% | +94.6% | +86.3% |
| RSI (14)Momentum oscillator 0–100 | 54.2 | 60.2 | 60.8 | 60.5 |
| Avg Volume (50D)Average daily shares traded | 869K | 1.4M | 2.8M | 1.2M |
Evenly matched — IMVT and CABA each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: KYTX as "Buy", IMVT as "Buy", CABA as "Buy", RCUS as "Buy". Consensus price targets imply 308.2% upside for CABA (target: $16) vs 21.0% for RCUS (target: $30).
| Metric | KYTXKyverna Therapeut… | IMVTImmunovant, Inc. | CABACabaletta Bio, In… | RCUSArcus Biosciences… |
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $32.67 | $45.50 | $16.33 | $30.00 |
| # AnalystsCovering analysts | 4 | 23 | 12 | 18 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | — | 1 | — |
| Dividend / ShareAnnual DPS | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | +0.1% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
CABA leads in 1 of 6 categories (Income & Cash Flow). IMVT leads in 1 (Total Returns). 3 tied.
Best OverallImmunovant, Inc. (IMVT)Leads 1 of 6 categories
Loading custom metrics...
KYTX vs IMVT vs CABA vs RCUS: Key Questions Answered
8 questions · data-driven answers · updated daily
01Is KYTX or IMVT or CABA or RCUS a better buy right now?
Analysts rate Kyverna Therapeutics, Inc.
(KYTX) a "Buy" — based on 4 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — KYTX or IMVT or CABA or RCUS?
Over the past 5 years, Immunovant, Inc.
(IMVT) delivered a total return of +62. 4%, compared to -69. 0% for Kyverna Therapeutics, Inc. (KYTX). Over 10 years, the gap is even starker: IMVT returned +173. 6% versus KYTX's -69. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — KYTX or IMVT or CABA or RCUS?
By beta (market sensitivity over 5 years), Immunovant, Inc.
(IMVT) is the lower-risk stock at 1. 37β versus Kyverna Therapeutics, Inc. 's 3. 05β — meaning KYTX is approximately 122% more volatile than IMVT relative to the S&P 500. On balance sheet safety, Immunovant, Inc. (IMVT) carries a lower debt/equity ratio of 0% versus 24% for Cabaletta Bio, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — KYTX or IMVT or CABA or RCUS?
On earnings-per-share growth, the picture is similar: Cabaletta Bio, Inc.
grew EPS 29. 9% year-over-year, compared to -45. 2% for Immunovant, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — KYTX or IMVT or CABA or RCUS?
Kyverna Therapeutics, Inc.
(KYTX) is the more profitable company, earning 0. 0% net margin versus -142. 9% for Arcus Biosciences, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: KYTX leads at 0. 0% versus -156. 3% for RCUS. At the gross margin level — before operating expenses — RCUS leads at 96. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — KYTX or IMVT or CABA or RCUS?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is KYTX or IMVT or CABA or RCUS better for a retirement portfolio?
For long-horizon retirement investors, Immunovant, Inc.
(IMVT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (+173. 6% 10Y return). Kyverna Therapeutics, Inc. (KYTX) carries a higher beta of 3. 05 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (IMVT: +173. 6%, KYTX: -69. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between KYTX and IMVT and CABA and RCUS?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.